Sandler SG, Flegel WA, Westhoff CM, et al. It’s time to phase in RHD genotyping for patients with a serologic weak D phenotype. Transfusion 2015;55:680–9.SandlerSGFlegelWAWesthoffCM,It’s time to phase in RHD genotyping for patients with a serologic weak D phenotype.2015;55:680–9.10.1111/trf.12941Search in Google Scholar
AABB. Joint statement on phasing-in RHD genotyping for pregnant women and other females of childbearing potential with a serologic weak D phenotype. Available from http://www.aabb.org/advocacy/statements/Pages/statement150722.aspx (February 9, 2017).AABB.. Available from http://www.aabb.org/advocacy/statements/Pages/statement150722.aspx (February 9, 2017).Search in Google Scholar
Keller MA, Crowley J, Horn T, et al. Characterization of RH locus in African American blood donors. Transfusion 2013; 53(2 Suppl):28A.KellerMACrowleyJHornT,Characterization of RH locus in African American blood donors.2013;53(2Suppl):28A.Search in Google Scholar
Queenan JT. Rh immunoprophylaxis and fetal RHD Genotyping: where are we going? Obstet Gynecol 2012;120: 219–20.QueenanJT.Rh immunoprophylaxis and fetal RHD Genotyping: where are we going?2012;120:219–20.10.1097/AOG.0b013e3182611bcbSearch in Google Scholar
Moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol 2012;120:1132–9.MoiseKJJrArgotiPS.Management and prevention of red cell alloimmunization in pregnancy: a systematic review.2012;120:1132–9.10.1097/AOG.0b013e31826d7dc1Search in Google Scholar
Hartwell EA. Use of Rh immune globulin: ASCP practice parameter. Am J Clin Pathol. 1998;110:281–92.HartwellEA.Use of Rh immune globulin: ASCP practice parameter.1998;110:281–92.10.1093/ajcp/110.3.281Search in Google Scholar
Reid M, Lomas-Francis C, Olsson M. The blood group antigen factsbook. 3rd ed. London: Academic Press; 2012:147–262.ReidMLomas-FrancisCOlssonM..3rd ed.London:Academic Press;2012:147–262.10.1016/B978-0-12-415849-8.00006-5Search in Google Scholar
Denomme GA, Wagner FF, Fernandes BJ, Li W, Flegel WA. Partial D, weak D types, and novel RHD alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization and prevention. Transfusion 2005;45:1554–60.DenommeGAWagnerFFFernandesBJLiWFlegelWA.Partial D, weak D types, and novel RHD alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization and prevention.2005;45:1554–60.10.1111/j.1537-2995.2005.00586.xSearch in Google Scholar
Flegel WA, Denomme GA, Yazer MH. On the complexity of D antigen typing: a handy decision tree in the age of molecular blood group diagnostics. J Obstet Gynaecol Can. 2007;29:746–52.FlegelWADenommeGAYazerMH.On the complexity of D antigen typing: a handy decision tree in the age of molecular blood group diagnostics.2007;29:746–52.10.1016/S1701-2163(16)32606-8Search in Google Scholar
Keller MA. The role of red cell genotyping in transfusion medicine. Immunohematology 2015;31:49–52.KellerMA.The role of red cell genotyping in transfusion medicine.2015;31:49–52.10.21307/immunohematology-2019-069Search in Google Scholar
Luo X, Keller MA, James I, et al. Strategies to identify candidates for D variant genotyping. Blood Transfus 2018;16:293–301.LuoXKellerMAJamesI,Strategies to identify candidates for D variant genotyping.2018;16:293–301.Search in Google Scholar
Hawk AF, Chang EY, Shields SM, Simpson KN. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis. Obstet Gynecol 2013;122:579–85.HawkAFChangEYShieldsSMSimpsonKN.Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis.2013;122:579–85.10.1097/AOG.0b013e31829f881423921866Search in Google Scholar
Clausen FB, Rieneck K, Krog GR, Bundgaard BS, Dziegiel MH. Noninvasive antenatal screening for fetal RHD in RhD negative women to guide targeted anti-D prophylaxis. Methods Mol Biol. 2019;1885:347–59.ClausenFBRieneckKKrogGRBundgaardBSDziegielMH.Noninvasive antenatal screening for fetal RHD in RhD negative women to guide targeted anti-D prophylaxis.2019;1885:347–59.10.1007/978-1-4939-8889-1_2330506209Search in Google Scholar
Chen Q, Flegel WA. Random survey for RHD alleles among D+ European persons. Transfusion 2005;45:1183–91.ChenQFlegelWA.Random survey for RHD alleles among D+ European persons.2005;45:1183–91.10.1111/j.1537-2995.2005.00181.x15987365Search in Google Scholar
Flegel WA. Blood group genotyping in Germany. Transfusion 2007;47(1 Suppl):47S–53S.FlegelWA.Blood group genotyping in Germany.2007;47(1Suppl):47S–53S.10.1111/j.1537-2995.2007.01310.x17593286Search in Google Scholar
Pham BN, Roussel M, Peyrard T, et al. Anti-D investigations in individuals expressing weak D type 1 or weak D type 2: allo- or autoantibodies? Transfusion 2011;51:2679–85.PhamBNRousselMPeyrardT,Anti-D investigations in individuals expressing weak D type 1 or weak D type 2: allo- or autoantibodies?2011;51:2679–85.10.1111/j.1537-2995.2011.03207.x21658048Search in Google Scholar
Hemker MB, Ligthart PC, Berger L, van Rhenen DJ, van der Schoot CE, Wijk PA. DAR, a new RhD variant involving exons 4, 5, and 7, often in linkage with ceAR, a new Rhce variant frequently found in African blacks. Blood 1999;94:4337–42.HemkerMBLigthartPCBergerLvan RhenenDJvan der SchootCEWijkPA.DAR, a new RhD variant involving exons 4, 5, and 7, often in linkage with ceAR, a new Rhce variant frequently found in African blacks.1999;94:4337–42.10.1182/blood.V94.12.4337Search in Google Scholar
Horn T, Crowley JA, Keller MA. RhD typing discrepancies resolved through RHD genotyping: a patient perspective. Transfusion 2014;54:29A.HornTCrowleyJAKellerMA.RhD typing discrepancies resolved through RHD genotyping: a patient perspective.2014;54:29A.Search in Google Scholar
Sandler SG, Roseff SD, Domen RE, Shaz B, Gottschall JL. Policies and procedures related to testing for weak D phenotypes and administration of Rh immune globulin: results and recommendations related to supplemental questions in the Comprehensive Transfusion Medicine survey of the College of American Pathologists. Arch Pathol Lab Med 2014;138:620–5.SandlerSGRoseffSDDomenREShazBGottschallJL.Policies and procedures related to testing for weak D phenotypes and administration of Rh immune globulin: results and recommendations related to supplemental questions in the Comprehensive Transfusion Medicine survey of the College of American Pathologists.2014;138:620–5.10.5858/arpa.2013-0141-CP24786120Search in Google Scholar
Kacker S, Vassallo R, Keller MA, et al. Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype. Transfusion 2015;55:2095–103KackerSVassalloRKellerMA,Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype.2015;55:2095–10310.1111/trf.13074473982325808011Search in Google Scholar
ISBT. Red cell immunogenetics and blood group terminology. Available from: http://www.isbtweb.org/working-parties/ red-cell-immunogenetics-and-blood-group-terminology/. Accessed 24 December 2020.ISBT.. Available from: http://www.isbtweb.org/working-parties/ red-cell-immunogenetics-and-blood-group-terminology/. Accessed 24 December 2020.Search in Google Scholar
The Human RhesusBase, version 2.5, http://www.rhesusbase.info/, update 2020-03-18. Accessed 24 December 2020.http://www.rhesusbase.info/, update 2020-03-18. Accessed 24 December 2020.Search in Google Scholar
Westhoff C, Nance S, Lomas-Francis C, Keller MA, Chou S. Experience with RHD*weak D type 4.0 in the USA. Blood Transfus 2019;17:91–3.WesthoffCNanceSLomas-FrancisCKellerMAChouS.Experience with RHD*weak D type 4.0 in the USA.2019;17:91–3.Search in Google Scholar
Wagner FF, Eicher NI, Jørgensen JR, Lonicer CB, Flegel WA. DNB: a partial D with anti-D frequent in Central Europe. Blood 2002;100:2253–6.WagnerFFEicherNIJørgensenJRLonicerCBFlegelWA.DNB: a partial D with anti-D frequent in Central Europe.2002;100:2253–6.10.1182/blood-2002-03-074212200394Search in Google Scholar
Flegel WA, Denomme GA, Queenan JT, et al. It’s time to phase out “serologic weak D phenotype” and resolve D types with RHD genotyping including weak D type 4. Transfusion 2020;60:855–9.FlegelWADenommeGAQueenanJT,It’s time to phase out “serologic weak D phenotype” and resolve D types with RHD genotyping including weak D type 4.2020;60:855–9.10.1111/trf.15741912135032163599Search in Google Scholar